Stock CRSP CRISPR THERAPEUTICS AG
Add to a list
To use this feature you must be a member
Log inSign up

All News CRISPR Therapeutics AG

Equities

CRSP

CH0334081137

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
51.17 USD -4.44% Intraday chart for CRISPR Therapeutics AG -8.45% -18.26%
May. 10 Oppenheimer Adjusts CRISPR Therapeutics Price Target to $95 From $102, Maintains Outperform Rating MT
May. 09 Barclays Adjusts Price Target on CRISPR Therapeutics to $67 From $80, Maintains Equal-Weight Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oppenheimer Adjusts CRISPR Therapeutics Price Target to $95 From $102, Maintains Outperform Rating
MT
Barclays Adjusts Price Target on CRISPR Therapeutics to $67 From $80, Maintains Equal-Weight Rating
MT
Needham Adjusts Price Target on CRISPR Therapeutics to $88 From $90, Keeps Buy Rating
MT
Baird Adjusts Price Target on CRISPR Therapeutics to $52 From $46, Keeps Neutral Rating
MT
CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
AQ
CRISPR Therapeutics AG Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q1 Revenue $504,000
MT
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
AQ
CRISPR Therapeutics : ASGCT 2024 Oral Presentation
PU
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach
AQ
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach
CI
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene and Cell Therapy 2024 Annual Meeting
AQ
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
AQ
Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating
MT
Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing
MT
Harvard University: How to realize immense promise of gene editing
AQ
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
AQ
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
AQ
Recent Appellate Decision Overturns Revocations Of Broad Institute CRISPR-Cas9 Patents
AQ
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRSP Stock
  4. News CRISPR Therapeutics AG
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW